{"denoms":[{"counts":[{"groupId":"BG000","value":"74"}],"units":"Participants"}],"groups":[{"description":"Patients ages 18-70 with primary refractory or relapsed myeloma, candidates for an autologous SCT (ASCT) who had previously received treatment with bortezomib, an immunomodulatory drug, or both, or who were receiving a salvage ASCT.","id":"BG000","title":"Gemcitabine/Busulfan/Melphalan"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.5","value":"58.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"57"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"55"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"1st SCT/salvage SCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Poor-risk cytogenetics"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Extramedullary disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Double refractory (IMiDs + proteasome inhibitors)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Disease Status: Primary refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Disease Status: Refractory relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Disease Status: Sensitive relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Response at ASCT: Response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Response at ASCT: Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"No. prior lines of treatment"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"No. prior lines of treatment > 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Post-ASCT maintenance"}],"paramType":"NUMBER","title":"Overall study group","unitOfMeasure":"participants"}]}